Physiologically relevant human models of chronic pain are essential to developing new therapeutics and overcome poor translation between animal studies and the clinical setting 1 . In this poster, we describe the development of sensory neurons derived from human induced pluripotent stem cells (hiPSCs) with a relevant expression profile. The method used for neuronal differentiation was derived from Young etal 2 an overview is shown in figure 1 .
Introduction

Sensory Neuron Qualification Electric Field Stimulation
. Sensory neuronal differentiation. Fully characterised hiPSCs were seeded as single cells and at low confluence onto Matrigel. Induction of differentiation was achieved by dual SMAD inhibition using the small molecules SB431542 and LDN193189 in Knockout Serum and neuronal media (KSR and N2B27). Neural crest cells were cryopreserved and quality control performed to determine quality and yield of neuronal cultures. Neural crest were then matured into functioning neurons using a cocktail of growth factors to facilitate sensory neuronal development. Protein level expression of the peripheral nervous system marker SOX10 and the sensory neuronal marker BRN3A were determined at day 46 using immunocytochemistry. At the gene expression level a panel of neural crest and sensory neuronal markers were used and include developmental transcription factors such as NEUROG1, OTX2, TFAP2B, POU4F1 and ISL1. Furthermore, the late sensory neuronal markers and important sensory neuronal targets were also measured. These include; RUNX1, SCN9A, SCN10A, NTRK1, and TRPV1.
Sensory Neuronal Subtype
Maturation and development of sensory neurons differentiated using the method described in this poster results in a mixed neuronal population that can be detected using antibodies associated with proteins expressed by these subtypes. Figure 4 shows expression of CGRP and substance P. This poster demonstrates that Cellectricon's Cellaxess Elektra system in combination with hiPSC-derived sensory neurons produced by Censo is well-suited to investigate compound effects on neuronal excitability, with high relevance to human pain conditions. Because of the high capacity of the platform, we can generate highly refined compounds ready for clinical testing from medium throughput compound libraries.
Conclusion
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The Cellaxess® Elektra system enables electric field stimulation (EFS) and monitoring of neuronal cell cultures directly in 384-well microplates. Calcium imaging is used to monitor action potentials in cells during EFS while a homogeneous electrical field is applied (Fig 5) . Figure 5. A) The Cellaxess Elektra system. Neuronal excitability is analysed by studying the EFS-induced calcium transients. Red circle denotes the area of the iPS cell mat affected by the electric field. B) The concentration response curves show example mechanisms that are active in Censo's hiPSCderived sensory neurons. C) Table 1 . Effect of clinical and tool compounds investigated in two healthy control lines.
